Status:
COMPLETED
Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes
Lead Sponsor:
Chungbuk National University Hospital
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Brief Summary
This study evaluates the efficacy and safety of the empagliflozin as add-on thearpy compared to insulin glargine-based antidiabetic agents (OADs) combination thearpy in patients with type 2 diabetes i...
Eligibility Criteria
Inclusion
- Are inadequately controlled with triple OADs (metformin, sulfonylurea, dipeptidyl peptidase inhibitor) as evidenced by HbA1c \>7.5% and \<12.0%
Exclusion
- Type 1 diabetes
- Gestional diabetes
- Diabetes due to secondary causes
- Receiving anticancer treatment
- Receiving glucocorticoids or immune-suppressants
- Have been treated with sodium glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering the study
- Have been treated with any type of insulin for more than 7 consecutive days within 3 months before entering the study
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03473262
Start Date
January 1 2017
End Date
July 18 2018
Last Update
October 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.